Scientific and Administrative Management Team
John R. Cashman. Ph.D.
President and Founder
John R. Cashman. Ph.D., President and Founder, has more than 32 years of experience in biomedical research as a researcher, consultant, entrepreneur or administrator. In 1997, he founded the Human BioMolecular Research Institute, a non-profit research institute dedicated to conducting fundamental and applied research to address important human diseases. Previously, he was Senior Scientist at the Seattle Biomedical Research Institute and prior to that, he was Associate Director for the IGEN Research Institute in Seattle, Washington. In 1984, he was appointed Assistant Professor of Chemistry and Pharmaceutical Chemistry at the University of California, San Francisco. He completed a postdoctoral fellowship in the Department of Chemistry at Harvard University in Cambridge, Massachusetts with Professor E.J. Corey (1982-1984). In 1990, Professor Corey received the Nobel Prize. Dr. Cashman received his Masters and doctorate degrees in Medicinal Chemistry from the University of Kansas, Lawrence, Kansas (1982). Prior to graduate school, he obtained bachelor degrees in chemistry and biology at the College of Creative Studies, University of California, Santa Barbara (1977). Dr. Cashman was a University of California Presidents Undergraduate Researcher (1974-1976), received a Sigma Xi Undergraduate Research fellowship (1975), was a PEW Scholar Nominee at the University of California, San Francisco (1986), received a March of Dimes Basil O’Connor Research Award (1986), was appointed Technical Advisor, San Francisco Estuary Project (1990) and was elected Fellow of the American Association for the Advancement of Science in 1996. In 1991, Dr. Cashman was appointed to the Editorial Advisory Board, Chemical Research in Toxicology and in 1999 he was appointed to the Editorial Advisory Board of Current Drug Metabolism. Dr. Cashman is the author of over 230 research articles or book chapters and 16 patents in the area of drug discovery and evaluation. He is extensively consulted by biotechnology, pharmaceutical industry and government in various areas of human drug development, drug safety evaluation, medicinal chemistry, pharmacogenetics and biochemical toxicology. Dr. Cashman is on the Board of Directors of three biotechnology companies.
Click Here to View a list of Publications by John R. Cashman, Ph.D
Charles M. Thompson. Ph.D.
Senior Scientist
Chuck Thompson Ph.D. is an internationally-recognized organophosphate bioorganic chemist with extensive experience in biochemistry, metabolism and pharmacology. Dr. Thompson received his bachelor degree in chemistry in 1978 from Rutgers University. He obtained his MS and PhD degrees in chemistry under the auspices of T Roy Fukuto at UC Riverside. Dr. Thompson conducted post-doctoral work at Harvard University under Professor EJ Corey and at UC Berkeley under Professor H Rapoport. His initial academic appointment was at Loyola University of Chicago (1985-1994) where he developed a research program in chemical synthesis (dianion chemistry) and organophosphorus chemistry/biochemistry while being promoted and tenured. In 1994 he accepted a position at the University of Montana in the Department of Chemistry and in 1997 moved to the College of Pharmacy, University of Montana where he became a full professor in 1995-1996. Over a span of 40 years, he has developed expertise in multiple areas and published over 120 peer-reviewed papers with a particular interest in bio-organic chemistry, toxicology and synthesis of organophosphorus compounds. Over his academic career, he has been awarded over $20 M in federal grants and contracts, served on numerous boards, founded a children’s science center in Montana (spectrUM), started a small biotech company (ATERIS Technologies), and taught in undergraduate, graduate and professional curricula. Chuck Thompson served as an HBRI board member for two decade and in 2018-2019, he joined HBRI as a research investigator. Concurrently, he serves as a Professor of Medicinal Chemistry at the University of Montana and a Senior Scientist at HBRI. Dr. Thompson is currently a principle investigator on an NIH grant awarded to HBRI (U01NS11208) to study novel therapeutic approaches to treat organophosphorus exposure.
Michael Sherman
Administrator
Since 2018 Mr. Sherman has served as the institute’s Administrator. He received his B.A. in Business Administration from the University of Phoenix in 2015.
Institute Affiliate Members
